Renal Function Among Thalassemia Patients Treated by a Oral Chelator Deferasirox
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Thalassemia Major patients developed Iron Overload due to blood transfusions and intestinal
iron absorption. Renal function caused by Iron overload was studied in a previous study and
shows principally tubular disfunction. In this previous study the Iron chelator used was
Deferrioxamine. In the last five years an oral Iron chelator was introduced and approved by
the FDA, Deferasirox, (Novartis, Switzerland and USA). The purpose of this study is to assess
the renal function in Thalassemia Major patients treated with this new oral iron chelator and
compare the results with our previous study.